Living with pulmonary arterial hypertension and QoL
We introduce the first Varifarma product indicated for the treatment of pulmonary arterial hypertension as part of the expansion of our rare diseases’ portfolio. For more information, see the brochure below.
Efficacy and safety in the treatment of pulmonary arterial hypertension
Improves exercise capacity
Improves quality of life
Significantly reduces disease-related impairment
Oral 20-mg tablets for twice-daily administration
Phosphodiesterase type 5 (PDE5) inhibitors
Mean pulmonary artery pressure and pulmonary vascular resistance improved from baseline with Tadalafil 20 mg and 40 mg.
A significant improvement in cardiac index was observed in patients receiving Tadalafil 40 mg. No changes were reported in systemic blood pressure.
- Tadalafilo en HPA j.jacc 2012.05.004.pdf
- Journal of the American College of Cardiology Vol. 60, No. 8, 2012 – Tadalafil for the Treatment of Pulmonary Arterial Hypertension. A Double-Blind 52-Week Uncontrolled Extension Study.